Farmas USA

Fase 2 para pulmon

http://www.mdlinx.com/pulmonology/medical-news-article/2015/07/13/ganetespib-docetaxel-advanced-nsclc-adenocarcinoma-hsp90/6222492/

Seguridad OK.
Objetivo primario no alcanzado.

Un grupo del estudio presenta un nivel interesante de Supervivencia Media a partir de 6 meses . ( no he podido leerlo muy bien porque voy en modo movil y me salta un pop up pidiendome que me suscriba ) En principio no es que entusiasme lo que leo ... alguien puede echar un vistazo?

SNTA

Edito: como es que no aparece esto en su pagina web ....

Esto es lo que pone:

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
Annals of Oncology, 07/13/2015
Ramalingam S, et al.
T his study was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non–small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination. Advanced lung adenocarcinoma patients treated with ganetespib in combination with docetaxel had an acceptable safety profile. While the study's primary end points were not met, significant prolongation of PFS and OS was observed in patients >6 months from diagnosis of advanced disease, a subgroup chosen as the target population for the phase III study.
Methods

Patients with one prior systemic therapy for advanced disease were eligible.
Docetaxel (75 mg/m2 on day 1) was administered alone or with ganetespib (150 mg/m2 on days 1 and 15) every 3 weeks.
The primary end points were progression–free survival (PFS) in two subgroups of the adenocarcinoma population: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS).
Results

Of 385 patients enrolled, 381 were treated.
Early in the trial, increased hemoptysis and lack of efficacy were observed in nonadenocarcinoma patients (n = 71); therefore, only patients with adenocarcinoma histology were subsequently enrolled.
Neutropenia was the most common grade ≥3 adverse event: 41% in the combination arm versus 42% in docetaxel alone.
There was no improvement in PFS for the combination arm in the eLDH (N = 114, adjusted hazard ratio (HR) = 0.77, P = 0.1134) or mKRAS (N = 89, adjusted HR = 1.11, P = 0.3384) subgroups.
In the intent–to–treat adenocarcinoma population, there was a trend in favor of the combination, with PFS (N = 253, adjusted HR = 0.82, P = 0.0784) and overall survival (OS) (adjusted HR = 0.84, P = 0.1139).
Exploratory analyses showed significant benefit of the ganetespib combination in the prespecified subgroup of adenocarcinoma patients diagnosed with advanced disease >6 months before study entry (N = 177): PFS (adjusted HR = 0.74, P = 0.0417); OS (adjusted HR = 0.69, P = 0.0191).
-----------------------------------------------------------------

Parece que en principio las noticias no son buenas, no cumple los objetivos previstos, pero se consigue una aumento en la esperanza de vida, ¿es asi? Mi ingles técnico de medicina no es muy bueno.

SNTA

EDITO:
Mirando en la web de Synta aparece un link en la sección de ganetespib con fecha 10/06/2015 en el cual se lee la misma información.
http://annonc.oxfordjournals.org/content/early/2015/06/09/annonc.mdv220.short?rss=1

Parece que es una noticia ya pasada que mdlinx.com ha reflotado.

SNTA. vaya, yo la he reflotado porque la acababan de subir a Nasdaqlandia.
fallo mio.

Posible influencia en NVAX

http://elpais.com/elpais/2015/07/13/ciencia/1436804828_769674.html

Vacuna que se inhala. Tiene muy buena pinta.

OCAT

Ocata Therapeutics (OCAT) Pre-Clinical Data to be Presented at International Congress on Systemic Lupus Erythematosus

at the 11th International Congress on Systemic Lupus Erythematosus, taking place in Vienna, Austria from September 2-6.

The results demonstrate promising potential therapeutic activity of a pluripotent stem cell-derived product for the treatment of autoimmune diseases such as lupus nephritis and Crohn's disease using Ocata’s proprietary Hemangio-derived Mesenchymal Cell (HMCTM) platform. This unique and proprietary HMC product has been shown to have highly potent immune-modulatory and anti-inflammatory activity and is potentially well-suited for commercial scale up with retention of therapeutic potency.

The data describes both ex-vivo and in-vivo evidence in a highly regarded pre-clinical model of lupus nephritis. Top line data supports a prior proof-of-concept study which showed that HMC treatment increased the lifespan of the lupus-prone mice. The current study expands upon the initial results and examines how HMCs significantly inhibit the progression of otherwise fatal glomerulonephritis. The abstract will be presented at the Vienna Congress Center on Friday, September 4, 2015.

“This presentation at the leading lupus meeting is an important first step in developing potential new breakthrough treatments for disabling autoimmune diseases like lupus nephritis, where there is no cure available today,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “Our preclinical research and patent estate firmly anchors our leading position in the development of this novel Restorative Immunology™ platform and gives Ocata the ability to partner the non-ophthalmic uses of its technology for the treatment of devastating autoimmune diseases.”

http://ir.ocata.com/press-releases/detail/2787

Y se hace eco el StreetInsider

GALE +1,76% en pre.....
A ver si nos vamos a las cercanías de los 2$....

GALE

La verdad es que cuando mire el grafico no pensaba yo que se fuera a detener en los 1,50 pero mira tú por donde anda ya rebotando ... Pues a disfrutarlo, hombre!

GALE